Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
$1.48
-4.5%
$0.81
$0.26
$16.50
$16.58M1.21962,244 shs75,356 shs
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$5.67
$3.42
$12.72
$54.38M2.55132,982 shs36,800 shs
FONAR Co. stock logo
FONR
FONAR
$16.01
-1.2%
$20.92
$12.13
$24.05
$102.51M1.1218,923 shs14,603 shs
IRIDEX Co. stock logo
IRIX
IRIDEX
$3.03
+3.8%
$2.78
$1.31
$3.65
$49.24M0.8233,670 shs20,762 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$40.14
+6.9%
$43.63
$3.16
$53.82
$1.30B-1.56300,999 shs416,658 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
-4.82%-1.99%+174.58%-34.80%-89.28%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
0.00%0.00%0.00%0.00%0.00%
FONAR Co. stock logo
FONR
FONAR
-1.17%-4.65%-28.14%-18.11%+2.30%
IRIDEX Co. stock logo
IRIX
IRIDEX
+3.77%-7.34%+18.36%+8.21%+33.48%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
+6.93%+6.22%-4.45%-13.32%+950.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
0.0363 of 5 stars
0.02.00.00.03.10.00.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.0395 of 5 stars
3.51.00.04.61.34.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/A$2.00-33.99% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.00
Buy$55.6038.52% Upside

Current Analyst Ratings

Latest EYES, BSGM, FONR, IRIX, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/5/2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$93.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
$20K828.80N/AN/A($0.33) per share-4.48
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$3.38M0.00N/AN/A$4.80 per share0.00
FONAR Co. stock logo
FONR
FONAR
$102.42M0.99$2.65 per share6.05$23.07 per share0.69
IRIDEX Co. stock logo
IRIX
IRIDEX
$51.87M0.95N/AN/A$0.59 per share5.14
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
-$29.04M-$4.80N/AN/AN/A-8,129.09%-820.34%5/20/2024 (Estimated)
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
-$8.92MN/A0.00N/AN/AN/A-13.58%-13.02%N/A
FONAR Co. stock logo
FONR
FONAR
$9.38M$1.848.70N/A12.63%8.47%6.45%5/20/2024 (Estimated)
IRIDEX Co. stock logo
IRIX
IRIDEX
-$9.57M-$0.59N/AN/AN/A-18.45%-75.18%-25.99%5/9/2024 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$2.97N/AN/AN/AN/A-79.65%-52.92%5/14/2024 (Estimated)

Latest EYES, BSGM, FONR, IRIX, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
IRIDEX Co. stock logo
IRIX
IRIDEX
-$0.05-$0.18-$0.13-$0.18$14.90 million$12.46 million
3/6/2024Q4 2023
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.31-$0.33-$0.02-$0.33N/AN/A
2/14/2024Q2 2024
FONAR Co. stock logo
FONR
FONAR
N/A$0.54+$0.54$0.54N/A$25.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/A
0.12
0.12
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
22.15
22.15
FONAR Co. stock logo
FONR
FONAR
N/A
9.35
9.15
IRIDEX Co. stock logo
IRIX
IRIDEX
N/A
2.12
1.35
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
14.89
14.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
7.16%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
FONAR Co. stock logo
FONR
FONAR
50.64%
IRIDEX Co. stock logo
IRIX
IRIDEX
20.10%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
9.30%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
47.20%
FONAR Co. stock logo
FONR
FONAR
8.58%
IRIDEX Co. stock logo
IRIX
IRIDEX
6.20%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
28.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
411.20 million10.16 millionOptionable
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
1513.14 million6.94 millionOptionable
FONAR Co. stock logo
FONR
FONAR
5616.33 million6.19 millionNot Optionable
IRIDEX Co. stock logo
IRIX
IRIDEX
11116.25 million15.25 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3332.46 million23.11 millionOptionable

EYES, BSGM, FONR, IRIX, and SLNO Headlines

SourceHeadline
Soleno Therapeutics (NASDAQ:SLNO) Stock Crosses Below Fifty Day Moving Average of $43.74Soleno Therapeutics (NASDAQ:SLNO) Stock Crosses Below Fifty Day Moving Average of $43.74
americanbankingnews.com - April 23 at 5:34 AM
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 19 at 4:05 PM
Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%
marketbeat.com - April 15 at 2:49 PM
Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)
marketbeat.com - April 14 at 8:45 PM
Soleno Therapeutics CEO sells over $780k in company stockSoleno Therapeutics CEO sells over $780k in company stock
investing.com - April 5 at 11:15 PM
Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of StockInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of Stock
insidertrades.com - April 4 at 6:49 AM
Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Kristen Yen Sells 2,218 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Kristen Yen Sells 2,218 Shares
marketbeat.com - April 4 at 12:21 AM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Sees Large Increase in Short InterestSoleno Therapeutics, Inc. (NASDAQ:SLNO) Sees Large Increase in Short Interest
marketbeat.com - March 31 at 10:14 PM
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 5.6%Soleno Therapeutics (NASDAQ:SLNO) Trading Up 5.6%
marketbeat.com - March 26 at 5:13 PM
SLNO Apr 2024 40.000 putSLNO Apr 2024 40.000 put
finance.yahoo.com - March 16 at 10:33 PM
SLNO Apr 2024 35.000 putSLNO Apr 2024 35.000 put
finance.yahoo.com - March 16 at 7:31 AM
Construction of Solenos $22M pipe factory in Saratoga underwayConstruction of Soleno's $22M pipe factory in Saratoga underway
bizjournals.com - March 11 at 10:09 AM
Were Not Worried About Soleno Therapeutics (NASDAQ:SLNO) Cash BurnWe're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn
finance.yahoo.com - March 11 at 10:09 AM
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 8 at 4:05 PM
Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
markets.businessinsider.com - March 8 at 7:23 AM
SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023
investorplace.com - March 7 at 12:02 AM
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
globenewswire.com - March 6 at 4:05 PM
Soleno Therapeutics Inc.Soleno Therapeutics Inc.
thestreet.com - February 24 at 10:38 PM
SLNO Apr 2024 65.000 callSLNO Apr 2024 65.000 call
finance.yahoo.com - February 22 at 9:51 PM
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceSoleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
finance.yahoo.com - February 22 at 8:41 AM
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceSoleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
globenewswire.com - February 22 at 8:00 AM
SLNO Mar 2024 40.000 callSLNO Mar 2024 40.000 call
ca.finance.yahoo.com - February 18 at 3:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioSig Technologies logo

BioSig Technologies

NASDAQ:BSGM
BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Second Sight Medical Products logo

Second Sight Medical Products

NASDAQ:EYES
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
FONAR logo

FONAR

NASDAQ:FONR
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.
IRIDEX logo

IRIDEX

NASDAQ:IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Soleno Therapeutics logo

Soleno Therapeutics

NASDAQ:SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.